With regard to practical and clinical perspectives, our findings confirm that smoking cessation using varenicline is a viable option for individuals with T2DM without significant adverse effects on glycemic control, as evidenced by stable fasting insulin, glucose, HbA1c, and HOMA-IR levels. The gene discussed is INS; the disease is type 2 diabetes mellitus.